AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUL 212 min read$GKOS

Thurman Alex R. sold $1.6M of GKOS

Thurman Alex R. (SVP & CHIEF FINANCIAL OFFICER) sold 10,000 shares of GLAUKOS Corp (GKOS) at $160.00 ($1.60M total) on 2026-07-16 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Thurman Alex R.
Published Jul 21, 2026, 8:26 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 21, 2026, 8:27 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$GKOS
Neutral
medium confidence
Mentioned
$GKOS
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GKOSNeutralLow
01

Why it matters

Traders may briefly reassess sentiment around insider confidence, but the pre-arranged nature reduces informational content versus unscheduled sales.

02

Market read

A CFO 10b5-1 sale of about $1.6M is disclosed, which is usually low-signal for fundamentals.

03

What to watch

Insider sales under 10b5-1 often occur regardless of company outlook; without accompanying buys or changes in guidance, the trading signal is weak.

Relevance 5/10Novelty 3/10Timing: Filed 2026-07-21 after-hours/late session, with sale dated 2026-07-16.

Background

This is an SEC Form 4 insider transaction by GKOS’s CFO, reported as an open-market sale under a pre-arranged 10b5-1 plan.

Company-level read

Ticker impact

$GKOSNeutralMedium confidence
Context

Form 4 shows GKOS CFO Thurman Alex R. sold 10,000 shares on 2026-07-16 under a pre-arranged 10b5-1 plan for about $1.6M.

Expected impact

Likely minimal price impact; any reaction should fade unless accompanied by other negative company news.

Evidence & confidence

The filing is a primary-source insider transaction, but it is explicitly under a pre-arranged 10b5-1 plan and does not disclose new fundamentals.

Market effects

Sector

No clear sector read-through from a single CFO 10b5-1 sale.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

The sale may be purely liquidity-driven under a scheduled 10b5-1 plan, so it should not be interpreted as a negative view on GKOS prospects.

Key entities

  • issuer
    GLAUKOS Corp

    Company whose insider transaction is disclosed on Form 4 (GKOS).

  • insider
    Thurman Alex R.

    SVP and Chief Financial Officer who sold 10,000 shares.

  • trading mechanism
    10b5-1 plan

    Pre-arranged plan that schedules trades, typically lowering interpretive value.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

GKOS insider trading history →

Related articles

OCT 9
$GKOSMed

Glaukos Strengthens Retinal Pipeline Through RevOpsis Licensing Deal

Glaukos Corporation (GKOS) licensed RO-104, a tri-specific biologic for retinal diseases, from RevOpsis Therapeutics. The deal grants GKOS exclusive rights to RevOpsis' RevMod platform for up to four additional candidates. GKOS stock fell 6.3% post-announcement but is up 42.8% year-to-date. The agreement aims to expand GKOS' retinal therapeutics pipeline and market presence.

theglobeandmail.com3 min
OCT 9
$GKOSMed

Glaukos Corp (GKOS) Reports Positive Phase 4 Trial Results for i

Glaukos Corp (GKOS) reported positive phase 4 trial results for its iDose TR implant, showing significant reduction in intraocular pressure. The company trades at a P/S ratio of 15.24, above historical and industry medians, reflecting growth expectations. It has a GF Score of 79, indicating strong growth and financial health despite unprofitability. Insiders sold $67.8M in shares over the past year, while institutional investors increased holdings.

gurufocus.com2 min
OCT 9
$GKOSMed

Glaukos Reveals Superior Intraocular Pressure Reduction With Novel Eye Therapy - Glaukos (NYSE:GKOS)

Glaukos (NYSE:GKOS) reported positive Phase 4 trial results for its iDose TR therapy combined with cataract surgery. The treatment reduced intraocular pressure by 11.1 mmHg vs. 7.4 mmHg for surgery alone, meeting primary efficacy goals. The study showed no serious safety issues. The therapy aims to improve patient compliance with long-lasting drug delivery. GKOS shares are up 0.12% at $161.49.

benzinga.com2 min
OCT 9
$GKOSMedAI 9/10

Glaukos Reports Positive Phase 4 Results for iDose TR

Glaukos Corp. reported positive Phase 4 results for its iDose TR glaucoma treatment, meeting the primary endpoint and showing superiority in reducing intraocular pressure. The company also secured an exclusive licensing agreement with RevOpsis Therapeutics for retinal disease treatments. Shares of Glaukos (GKOS) were trading at $161.16 with a $9.5 billion market cap.

ocbj.com2 min